Page 39 - Read Online

JP, Kallioniemi O, Screpanti I, Poellinger L, Sahlgren C, Lendahl U. IM. The epidemiology of gastroenteropancreatic neuroendocrine
Non-canonical Notch signaling activates IL-6/JAK/STAT signaling tumors. Endocrinol Metab Clin North Am 2011;40:1-18, vii.
in breast tumor cells and is controlled by p53 and IKKalpha/ 22. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui
IKKbeta. Oncogene 2013;32:4892-902. CC, Clevers H, Dotto GP, Radtke F. Notch1 functions as a tumor
4. Kwon C, Cheng P, King IN, Andersen P, Shenje L, Nigam V, suppressor in mouse skin. Nat Genet 2003;33:416-21.
Srivastava D. Notch post-translationally regulates beta-catenin 23. Dongre A, Surampudi L, Lawlor RG, Fauq AH, Miele L, Golde TE,
protein in stem and progenitor cells. Nat Cell Biol 2011;13:1244-51. Minter LM, Osborne BA. Non-Canonical Notch Signaling Drives
5. Perumalsamy LR, Nagala M, Banerjee P, Sarin A. A hierarchical Activation and Differentiation of Peripheral CD4(+) T Cells. Front
cascade activated by non-canonical Notch signaling and the mTOR- Immunol 2014;5:54.
Rictor complex regulates neglect-induced death in mammalian 24. Minter LM, Osborne BA. Canonical and non-canonical Notch signaling
cells. Cell Death Differ 2009;16:879-89. in CD4(+) T cells. Curr Top Microbiol Immunol 2012;360:99-114.
6. Shin HM, Tilahun ME, Cho OH, Chandiran K, Kuksin CA, 25. Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP, Brennan
Keerthivasan S, Fauq AH, Golde TE, Miele L, Thome M, Osborne K. Notch activation induces Akt signaling via an autocrine
BA, Minter LM. NOTCH1 can initiate NF-kappaB activation via loop to prevent apoptosis in breast epithelial cells. Cancer Res
cytosolic interactions with components of the T cell signalosome. 2009;69:5015-22.
Front Immunol 2014;5:249. 26. Crabtree JS, Singleton CS, Miele L. Notch Signaling in Neuroendocrine
7. Bocchetta M, Miele L, Pass HI, Carbone M. Notch-1 induction, a Tumors. Front Oncol 2016;6:94.
novel activity of SV40 required for growth of SV40-transformed 27. Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional
human mesothelial cells. Oncogene 2003;22:81-9. regulation at Notch target genes. Cell Mol Life Sci 2009;66:1631-46.
8. Carter Y, Jaskula-Sztul R, Chen H, Mazeh H. Signaling pathways as 28. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez
specific pharmacologic targets for neuroendocrine tumor therapy: JA, Martinez Del Prado MP, Alonso Orduna V, Sevilla-Garcia I,
RET, PI3K, MEK, growth factors, and Notch. Neuroendocrinology Villabona-Artero C, Beguiristain-Gomez A, Llanos-Munoz M,
2013;97:57-66. Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jimenez-
9. Hassan WA, Yoshida R, Kudoh S, Hasegawa K, Niimori-Kita K, Ito Fonseca P, Teule A, Sastre-Valera J, Benavent-Vinuelas M,
T. Notch1 controls cell invasion and metastasis in small cell lung Monleon A, Salazar R. Incidence, patterns of care and prognostic
carcinoma cell lines. Lung Cancer 2014;86:304-10. factors for outcome of gastroenteropancreatic neuroendocrine
10. Krausch M, Kroepil F, Lehwald N, Lachenmayer A, Schott M, Anlauf tumors (GEP-NETs): results from the National Cancer Registry of
M, Cupisti K, Knoefel WT, Raffel A. Notch 1 tumor expression is Spain (RGETNE). Ann Oncol 2010;21:1794-803.
lacking in highly proliferative pancreatic neuroendocrine tumors. 29. Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and
Endocrine 2013;44:182-6. survival evidence from a large population-based study (n = 25 531).
11. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 Ann Oncol 2013;24:3040-4.
signaling in neuroendocrine tumors. Oncologist 2007;12:535-42. 30. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla
12. Kunnimalaiyaan M, Yan S, Wong F, Zhang YW, Chen H. Hairy EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred
Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth years after “carcinoid”: epidemiology of and prognostic factors for
of carcinoid tumor cells. Surgery 2005;138:1137-42; discussion 42. neuroendocrine tumors in 35,825 cases in the United States. J Clin
13. Meder L, Konig K, Ozretic L, Schultheis AM, Ueckeroth F, Ade Oncol 2008;26:3063-72.
CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, Buhl 31. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen
T, Hartmann W, Wolf J, Merkelbach-Bruse S, Eilers M, Perner S, M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF,
Heukamp LC, Buettner R. NOTCH, ASCL1, p53 and RB alterations Oberg K, O’Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen
define an alternative pathway driving neuroendocrine and small cell CY, Washington MK, Wiedenmann B, Yao J. Pathology reporting
lung carcinomas. Int J Cancer 2016;138:927-38. of neuroendocrine tumors: application of the Delphic consensus
14. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah process to the development of a minimum pathology data set. Am J
S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Surg Pathol 2010;34:300-13.
Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland 32. Strosberg J. Neuroendocrine tumours of the small intestine. Best
B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio Pract Res Clin Gastroenterol 2012;26:755-73.
A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, 33. Kunz PL. Carcinoid and Neuroendocrine Tumors: Building on
Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ. A DLL3- Success. J Clin Oncol 2015;33:1855-63.
targeted antibody-drug conjugate eradicates high-grade pulmonary 34. National Comprehensive Cancer Network. NCCN clinical practice
neuroendocrine tumor-initiating cells in vivo. Sci Transl Med guidelines in oncology: neuroendocrine tumors v, 2016. Updated
2015;7:302ra136. 5/25/2016, accessed 7/28/16. In.
15. Andersson ER, Lendahl U. Therapeutic modulation of Notch 35. Susini C, Buscail L. Rationale for the use of somatostatin analogs as
signalling -- are we there yet? Nat Rev Drug Discov 2014;13:357-78. antitumor agents. Ann Oncol 2006;17:1733-42.
16. Chikara S, Reindl KM. Notch signaling: a hero or villain in the war 36. Cives M, Strosberg J. The expanding role of somatostatin analogs
against cancer? Transl Lung Cancer Res 2013;2:449-51. in gastroenteropancreatic and lung neuroendocrine tumors. Drugs
17. D’Souza B, Miyamoto A, Weinmaster G. The many facets of Notch 2015;75:847-58.
ligands. Oncogene 2008;27:5148-67. 37. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied
18. Espinoza I, Miele L. Notch inhibitors for cancer treatment. M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold
Pharmacol Ther 2013;139:95-110. C, Gress T, Arnold R, Group PS. Placebo-controlled, double-blind,
19. Hirata N, Yamada S, Shoda T, Kurihara M, Sekino Y, Kanda Y. prospective, randomized study on the effect of octreotide LAR in the
Sphingosine-1-phosphate promotes expansion of cancer stem cells control of tumor growth in patients with metastatic neuroendocrine
via S1PR3 by a ligand-independent Notch activation. Nat Commun midgut tumors: a report from the PROMID Study Group. J Clin
2014;5:4806. Oncol 2009;27:4656-63.
20. Andersen P, Uosaki H, Shenje LT, Kwon C. Non-canonical 38. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova
Notch signaling: emerging role and mechanism. Trends Cell Biol E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A,
2012;22:257-65. Martinez S, Blumberg J, Ruszniewski P, Investigators C. Lanreotide
21. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin in metastatic enteropancreatic neuroendocrine tumors. N Engl J
288
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 17, 2016 ¦